• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » HitGen partners with Scripps Research Institute and Calibr

HitGen partners with Scripps Research Institute and Calibr

April 24, 2017
CenterWatch Staff

HitGen, a privately held biotech company focused on technology for effective and efficient small molecule drug discovery and development, announced a collaboration with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr). This collaboration is to discover and develop potential new therapies in areas of unmet clinical need, with an initial focus in oncology, regenerative medicine and virology.

HitGen’s technology platform, centered around the design, synthesis, and interrogation of multi‐billion component libraries of DNA encoded small molecules, will be deployed to identify new small molecule leads for therapeutic targets identified by the collaboration. Leaders in basic and translational research at TSRI and Calibr will provide target materials and relevant know‐how to prosecute drug targets of interest. The parties will contribute in‐kind to the discovery efforts and anticipate progressing any drug candidates that emerge to clinical proof‐of‐concept studies.

“We are delighted to partner with HitGen to further the combined TSRI‐Calibr mission to create new medicines for unmet needs. HitGen’s commitment to developing and deploying DEL technology is a great fit for our new model for translational research in the non‐profit sector,” commented Peter Schultz, President and Professor of Chemistry at TSRI, and CEO of Calibr.

“We are excited to collaborate with Prof. Schultz and his colleagues at TSRI‐Calibr as a strategic partner for these discovery efforts, and we acknowledge the fundamental contributions of TSRI Professors Sydney Brenner and Richard Lerner in initiating the field of DNA‐encoded chemistry technology,” said Dr. Jin Li, chairman and CEO of HitGen. “HitGen continues to grow as a world‐class drug discovery organization. We are keenly focused on engaging with world‐leading academic institutions to provide new solutions for unmet medical need.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing